Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Lebowitz - Citigroup - Analyst : Before we start digging in, and this has obviously been a very eventful year for the company, starting -- I only initiated about literally, I think about a year ago. It was by design, of course. The -- you had a big year, tell us about the company itself the overall strategy of what you're trying to do and certainly specifically in the endocrine space.

Question: David Lebowitz - Citigroup - Analyst : Absolutely. One question I would add, and this is more from the top level is you have a variety of indications that you're targeting across your entire pipeline. And many of these treatment -- these indications have treatments available on the market, albeit flawed treatments available, where many of these markets haven't evolved much over a very long period of time and have been pretty static. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference Is that your overall goal to look at specific markets where there is some history, but it's just insufficient? Or are you also going to look at more developing markets and opportunities that have nothing available?

Question: David Lebowitz - Citigroup - Analyst : Now, a lot of pipeline products. Where would you like to start?

Question: David Lebowitz - Citigroup - Analyst : Let's do it.

Question: David Lebowitz - Citigroup - Analyst : Have there been prior efforts that you know about with small molecule drug conjugates in the past? And what have you learned from those? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: David Lebowitz - Citigroup - Analyst : Now could you run us through what you think some perceived potential advantages could be versus an antibody drug conjugate. But conversely, what also are the potential risks that might be if you're comparing these to each other?

Question: David Lebowitz - Citigroup - Analyst : Got it. So you have a lot of INDs that are going in, some have already gone in. Could you tell us about some of these new candidates and what we should expect to see, certainly, polycystic kidney disease is one area Grave's disease had.

Question: David Lebowitz - Citigroup - Analyst : For those not acquainted, can you run us through what the path towards market is for a drug to treat polycystic kidney disease?

Question: David Lebowitz - Citigroup - Analyst : So the initial IND, would that be something that would be more geared towards healthy patients in determining the properties and then going towards a more diseased population?

Question: David Lebowitz - Citigroup - Analyst : Got it. So let's jump from the early to the more recent. Paltusotine, obviously, it's been a big year. First, coming down the pipeline and nearing the end of the pipeline, so to speak, is acromegaly just run -- give us a rundown of what acromegaly is and how it is currently treated? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: David Lebowitz - Citigroup - Analyst : Now you ran two pivotal trials, PATHFNDR-1 and PATHFNDR-2. Could you tell us about the differences between these two trials?

Question: David Lebowitz - Citigroup - Analyst : Now given that SSA has been around for a while, and you're thinking about launching in a lot of ways, you're going against inertia just because it's been there. With that in mind, and given the data that we presented to date, clearly an oral and the challenges with SSA is going to be something appealing. How should we look at it as far as we're thinking about the launch about what uptake looks like when you're talking inertia versus innovation? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: David Lebowitz - Citigroup - Analyst : Are lot of those patients identified and out there, so you know where they are and there will be easy to find? Or what type of effort is it to get in contact with these people who are selectively not in the system?

Question: David Lebowitz - Citigroup - Analyst : So let's jump to carcinoid syndrome. Similar data in a similar time frame, obviously, earlier stage. You recently announced a Phase 3 trial design for the Care Finder studies, which I looked in my notes, I wrote as Car Finder. In fact that Care Finders trial--

Question: David Lebowitz - Citigroup - Analyst : So I guess tell us about that trial design, tell us about how that market is currently treated? And I guess, a similar dynamics of what your expectations are relative to paltusotine.

Question: David Lebowitz - Citigroup - Analyst : How should we think about that trial in terms of time line?

Question: David Lebowitz - Citigroup - Analyst : Sounds great. Boston, earlier this year, you had some intriguing data for both CAH and for Cushing's with your next candidate. Tell us about what you presented, this will start with CAH and how this could be a game changer for these patients.

Question: David Lebowitz - Citigroup - Analyst : We were actually having a doctor call the moment the abstracts came out and we were having a conversation, and it was shaped around expectations for atumelnant relative to crinecerfont. And literally, the doctor was saying, well, finds the CRF1 mechanism intriguing, not so sure about ACTH, then boom, the abstracts came out and he read it over there and he literally did a 360, I guess it will be 180 and said that the data was very impressive. It changed expectations about what could be possible for treating the disease. And one thing that he particularly here in and was the impact on menstrual cycles for these patients as something that he never would have anticipated. Was that type of effect -- I mean initially, people were talking about weaning off of corticosteroid reduction as being the objective. Did you see something like that? How do you think doctors will think in terms of what their expectations are for treating these patients?

Question: David Lebowitz - Citigroup - Analyst : Similarly, in Cushing's disease, what did you see that -- I mean, it probably didn't exceed your expectations, but you think might have exceeded the expectations of practitioners REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: David Lebowitz - Citigroup - Analyst : So could you tell us about next steps when we expect to see data? And what the path towards market might look like?

Question: David Lebowitz - Citigroup - Analyst : What would you say that the Phase 3 program would ultimately look like?

Question: David Lebowitz - Citigroup - Analyst : Got it. When investors are comparing different approaches and mechanisms out there, would you -- anything you would highlight different between what's happening with the crinecerfonts of the world and people on that end of spectrum with your mechanism? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 2:30PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: David Lebowitz - Citigroup - Analyst : So we're getting towards the end here. And we have a couple of minutes left. You certainly -- a lot of the questions given -- the questions you've gotten before, it's people educating on certainly what's the latest in the pipeline. If you were to free style here and want to talk about what do you want people to know and it can be anything. What do you see as far as the overall direction going forward, not just with the INDs, but just directionally where you see this company moving?

Question: David Lebowitz - Citigroup - Analyst : Excellent. That's very helpful. That's great. And thank you very much for your time and look forward to chatting in soon.